AN association between high Ly-6A/E expression on tumor cells and a highly malignant phenotype
- 1 December 1994
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 59 (5) , 684-691
- https://doi.org/10.1002/ijc.2910590517
Abstract
Murine Ly-6 is a molecule expressed by various cells, including several types of hematopoietic cells such as pluripotent stem cells, and activated T cells. Ly-6 is also expressed on tumor cells originating from a variety of tissues. Preliminary observations suggested that the expression of Ly-6A/E is up-regulated on highly tumorigenic variants of polyoma-virus(PyV)-transformed BALB/c 3T3 cells as compared with weakly tumorigenic variants. On the basis of these observations, we sorted PyV-transformed A3C cells or DA3 mammary adenocarcinoma cells into stable sub-populations expressing high or low levels of membrane or mRNA Ly-6A/E. In vivo studies indicated that the high-Ly-6A/E-expressing cells in both tumor systems expressed a considerably more malignant phenotype (higher efficiency in local tumor production as well as in lung colonization) than low-Ly-6A/E expressors. Since the high-Ly-6A/E expressors did not exhibit any growth advantage in vitro over low Ly-6A/E expressors, we concluded that interactions of the former cells with micro-environmental factors operating in vivo (e.g., Ly-6A/E ligands) conferred upon these cells a highly malignant phenotype. Apart from the difference in Ly-6A/E expression, no other phenotypic characteristics distinguished highly from weakly malignant tumor cells. Similarly to T cells, where antibodies to Ly-6 transduce (or co-transduce) a proliferative signal, antibodies to Ly-6A/E were found to transduce a mitogenic signal to high-Ly-6A/E-expressing tumor cells but not to low-Ly-6A/E expressors. Taken together, these results show that Ly-6A/E expression is directly or indirectly associated in vivo with a highly malignant phenotype of 2 types of non-lymphoid murine tumors.Keywords
This publication has 16 references indexed in Scilit:
- In vivo tumorigenicity and in vitro sensitivity to tumor-necrosis-factorα mediated killing of c-Ha-ras-transformed cellsCancer Immunology, Immunotherapy, 1992
- Possibilities of Interference with the Immune System of Tumor Bearers by Non-Lymphoid FcγRII Expressing Tumor CellsImmunobiology, 1992
- Overlapping but Nonidentical Binding Sites on CD2 for CD58 and a Second Ligand CD59Science, 1992
- Inhibition of Ly-6A antigen expression prevents T cell activation.The Journal of Experimental Medicine, 1990
- Gene for human CD59 (likely Ly-6 homologue) is located on the short arm of chromosome 11Immunogenetics, 1989
- Demonstration of phosphatidylinositol anchors on Ly-6 molecules by specific phospholipase C digestion and gel electrophoresis in octylglucosideBiochemical and Biophysical Research Communications, 1987
- Murine Ly-6 multigene family is located on chromosome 15.Proceedings of the National Academy of Sciences, 1987
- Role of Ly-6 in lymphocyte activation. II. Induction of T cell activation by monoclonal anti-Ly-6 antibodies.The Journal of Experimental Medicine, 1986
- Interferon‐α/β enhances the expression of Ly‐6 antigens on T cells in vivo and in vitroEuropean Journal of Immunology, 1986
- Ly-6.2: A new lymphocyte specificity of peripheral T-cellsImmunogenetics, 1977